CV Sciences, Inc.

CVSI • Drug Manufacturers - Specialty & Generic

$0.01

— 0.00 (0.00%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$2.05M

Crecimiento

—

Flujo de caja

1/5

Tendencia

Volatile

Evidencia

Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 19 ago 2026, 12:21 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$0.01

Change0.00%

Shares Out205.09M

Market Cap$2.05M

Enterprise Value$3.04M

52W Range0.02 - 0.10

Beta0.49

P/E-1.02

P/S0.21

P/B1.31

P/FCF-3.93

EV/Sales0.31

Price$0.01

Change0.00%

Shares Out205.09M

Market Cap$2.05M

Enterprise Value$3.04M

52W Range0.02 - 0.10

Beta0.49

P/E-1.02

P/S0.21

P/B1.31

P/FCF-3.93

EV/Sales0.31

EV/EBITDA-2.58

EV/FCF-5.82

Earnings Yield-97.81%

FCF Yield-25.45%

Dividend Yield0.00%

Gross Margin48.97%

Oper. Margin-7.19%

Profit Margin-6.95%

Debt/Eq1.10

Current Ratio1.03

Quick Ratio0.21

Volume154.00K

Avg Volume651.32K

EPS Surprise0.02

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

36/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

67/100

Por qué este puntaje▼

Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

CVSI

Analyst sentiment

Based on 4 analyst votes · 2026-10-21

50/100

Neutral

Bullish

Hold

Bearish

Resumen de la compañía

IPO: 2/12/2013

Industria: Drug Manufacturers - Specialty & Generic

P/B i: 1.31

Deuda / Patrimonio i: 1.10

Margen operativo: -7.19%

Margen neto: -6.95%

ROE i: -

ROIC: -

Salud financiera

Puntaje7 / 20

Deuda / Patrimonio: 1.10

Ratio corriente: 1.03

Ratio rápido: 0.21

Estado: Weak

Advertencias

Weak quick ratio

Transacciones internas

Actividad reciente de ejecutivos e insiders

⚠ 2 venta interna de alto volumens detectadas

McCorkle William

Transacción: 02/18/2025

COMPRA

Cambio

+500,000

Precio

$0.04

Presentación

02/20/2025

Tipo

COMPRA

Dowling Joseph D

Transacción: 02/18/2025

COMPRA

Cambio

+3,000,000

Precio

$0.04

Presentación

02/20/2025

Tipo

COMPRA

Grasser Joerg

Transacción: 02/18/2025

COMPRA

Cambio

+2,350,000

Precio

$0.04

Presentación

02/20/2025

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
McCorkle William	COMPRA	+500,000	$0.04	02/18/2025	02/20/2025
Dowling Joseph D	COMPRA	+3,000,000	$0.04	02/18/2025	02/20/2025
Grasser Joerg	COMPRA	+2,350,000	$0.04	02/18/2025	02/20/2025
Corroon James Michael Jr.	COMPRA	+500,000	$0.04	02/18/2025	02/20/2025
Dowling Joseph D	COMPRA	+3,000,000	$0.05	06/20/2024	06/24/2024
Grasser Joerg	COMPRA	+2,350,000	$0.05	06/20/2024	06/24/2024
Corroon James Michael Jr.	COMPRA	+500,000	$0.05	06/20/2024	06/24/2024
McCorkle William	COMPRA	+500,000	$0.05	06/20/2024	06/24/2024
Grasser Joerg	COMPRA	+1,250,000	$0.04	03/15/2023	03/17/2023
Dowling Joseph D	COMPRA	+2,500,000	$0.04	03/15/2023	03/17/2023
McCorkle William	OTRO	0	Not reported	10/21/2022	11/07/2022
McCorkle William	COMPRA	+500,000	Not reported	10/21/2022	11/07/2022
Corroon James Michael Jr.	COMPRA	+500,000	$0.03	08/12/2022	08/15/2022
Corroon James Michael Jr.	VENTA	0	Not reported	07/21/2022	07/29/2022
Dowling Joseph D	VENTA	-100,000	Not reported	03/30/2022	04/01/2022
Grasser Joerg	VENTA	-250,000	Not reported	03/30/2022	04/01/2022
GRAHAM TERRI F	COMPRA	+275,000	$0.39	06/02/2021	06/03/2021
MAROON JOSEPH C MD	COMPRA	+275,000	$0.39	06/02/2021	06/03/2021
Altman Elizabeth Ann	COMPRA	+275,000	$0.39	06/02/2021	06/03/2021
BLAKE PAUL	COMPRA	+275,000	$0.39	06/02/2021	06/03/2021

Sobre la compañía

CV Sciences, Inc.

CV Sciences, Inc. functions as a life sciences organization primarily operating across North America. Its business activities are organized into two distinct divisions: Consumer Products and Specialty Pharmaceutical. The Consumer Products division focuses on the creation, manufacturing, and commercialization of plant-derived dietary supplements and cannabidiol (CBD) products sourced from hemp. These offerings are marketed under various brand identities including PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet. They serve a wide array of health and wellness sectors such as nutraceuticals, personal care, specialty food items, and pet products. The company distributes these goods through its own digital platforms, other online retailers, a network of chosen distributors, and traditional brick-and-mortar stores. In contrast, the Specialty Pharmaceutical division is dedicated to the research, advancement, and eventual market launch of cannabinoids for the treatment of specific medical conditions. A key project in this segment involves the drug candidate CVSI-007, an innovative combination of CBD and nicotine designed to combat smokeless tobacco use and dependence. Established in 2010, the company was initially known as CannaVest Corp. before officially adopting the name CV Sciences, Inc. in January 2016. Its main corporate offices are located in San Diego, California.

Fuente - Link

Competidores

AUSAF AYRWF AYURF BQST BUDZ CBIH DHBUF HYEX IONKF THCBF

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

CV Sciences, Inc. (OTCMKTS:CVSI) Shares Shorted: Short Interest Up 123.1% in September

CV Sciences, Inc. (OTCMKTS:CVSI - Get Free Report) saw a large growth in short interest in the month of September. As of September 30th, there was short interest totaling 14,190 shares, a growth of 123.1% from the September 15th total of 6,360 shares. Currently, 0.0% of the shares of the stock are short sold. Based

Defense World

CV Sciences Welcomes Enactment of Federal Legislation Providing Additional Time for a Responsible, Science-Based Hemp Regulatory Framework

Legislation delays implementation of new federal hemp restrictions until December 11, 2026, preserving continued access to naturally derived hemp products SAN DIEGO, CA / ACCESS Newswire / September 8, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today welcomed the enactment of federal legislation that delays implementation of significant changes to the federal definition of hemp and provides additional time for Congress and the Administration to develop a comprehensive regulatory framework for hemp-derived cannabinoid products. The legislation passed the U.S. House of Representatives by a bipartisan vote of 370-48 and the Senate by a vote of 90-6, President Trump signed the legislation into law on September 1.

Accesswire

CV Sciences (OTCMKTS:CVSI) Shares Cross Below 50 Day Moving Average – What’s Next?

CV Sciences, Inc. (OTCMKTS:CVSI - Get Free Report)'s stock price crossed below its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $0.02 and traded as low as $0.0180. CV Sciences shares last traded at $0.0191, with a volume of 199,238 shares changing hands. CV Sciences

Defense World

CV Sciences, Inc. (CVSI) Q2 2026 Earnings Call Transcript

Seeking Alpha

CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results

SAN DIEGO, CA / ACCESS Newswire / August 13, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended June 30, 2026. Second Quarter 2026 and Recent Financial, Operating and Regulatory Highlights Generated revenue of $3.0 million for the second quarter 2026 compared to $3.6 million for the second quarter 2025 and compared to $3.2 million for the first quarter 2026; Recognized gross margin of 48.6% for the second quarter 2026 compared to 50.9% for the second quarter 2025 and compared to 48.9% for the first quarter 2026; Cash balance of $0.3 million at quarter and year end; Reduced operating expenses by 11.3% to $1.7 million for the second quarter 2026 compared to $2.0 million for the second quarter 2025, and by 6.9% from $1.9 million in the first quarter 2026; Recognized an adjusted EBITDA loss of $0.1 million for the second quarter 2026 compared to positive adjusted EBITDA of $0.1 million for second quarter 2025 and compared to an adjusted EBITDA loss of $0.1 million for the first quarter 2026; Expanded the +PlusHLTH™ portfolio with personalized wellness solutions for healthy aging; Launched PlusHLTH.com, a new dedicated e-commerce platform strengthens the Company's strategy to build a leading science-backed health and wellness portfolio; and U.S. Senate voted 61-32 to approve Continuing Resolution H.R.

Accesswire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-14	-0.02	-0.0034	0.0166
2026-03-26	-0.01	-0.0011	0.0089
2024-08-13	-0.03	-0.03	0
2024-05-14	-0.03	-0.02	0.01
2024-03-28	-0.01	-0.01	0
2023-11-14	-0.01	-0.00289	0.00711
2023-08-14	-0.01	-0.01	0
2023-05-15	-0.01	0.04	0.05
2023-03-29	-0.02	-0.02	0
2022-11-14	-0.02	-0.01	0.01
2022-08-15	-0.03	-0.03	0
2022-05-16	-0.015	-0.02	-0.005